Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)-Reference-Cited by-同舟云学术

Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)

Published:2016-10 Issue:2 Volume:86 Page:249-251
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Jones Ronald N.,Rhomberg Paul R.,Mendes Rodrigo E.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference17 articles.

1. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates;Biedenbach;Antimicrob Agents Chemother,2009

2. Once-weekly dalbavancin versus daily conventional therapy for skin infection;Boucher;N Engl J Med,2014

3. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition;Clinical and Laboratory Standards Institute (CLSI),2015

4. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement;Clinical and Laboratory Standards Institute (CLSI),2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides;Antimicrobial Agents and Chemotherapy;2022-06-21

2. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections;International Journal of Antimicrobial Agents;2020-12

3. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen;Clinical Microbiology and Infection;2018-04

4. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers;Antimicrobial Agents and Chemotherapy;2018-03